INTRODUCTION
Following significant increases in life expectancy, 40% of individuals with Down syndrome (trisomy of chromosome 21) in the United Kingdom are now aged 40 years and older [1] with similar increases reported in the United States of America [2] . Alzheimer's disease is most likely universal in older individuals with Down syndrome, due to having three copies of the amyloid precursor protein (APP) gene, resulting in amyloid-beta deposition in plaques [3] . Down syndrome is, therefore, an important population in which to consider clinical trials of treatments to prevent or delay the development of dementia due to Alzheimer's disease. However, assessment of more subtle cognitive changes in adults with Down syndrome is challenging due to the presence of intellectual disability. This review will consider recent research on cognitive decline and dementia in people with Down syndrome, including epidemiology, clinical and neuropsychological assessment, comorbidities and advances in biomarkers such as neuroimaging.
EPIDEMIOLOGY
There is a sharp increase in dementia prevalence in older adults with Down syndrome, from less than 10% by age 49 years to more than 30% at 60 years [3] . As dementia is associated with high mortality rates, longitudinal data are required to estimate morbid risk. In a 14-year longitudinal study, the cumulative incidence for Alzheimer's disease in women with Down syndrome was estimated to be more than 80% by age 65 years; the mean age at dementia diagnosis was 55.41 years (SD ¼ 7.14) and median survival was 7 years after diagnosis [4 && ]. Alexander et al. [5] compared age-specific incidence of previously recognized common cardiovascular, central nervous system, psychiatric, digestive and endocrine disorders in 6430 individuals with Down syndrome (3009 women and 3421 men) and 19 176 general population controls (8966 women and 10 210 men) using the United Kingdom Clinical Practice Research Datalink in a matched retrospective cohort study. They found a median age of 47 years for dementia diagnosis, with dementia incidence more than 90 times higher [incidence relative risk (IRR) 92.1; 54.3-156.2; P < 0.001] than in controls.
CLINICAL ASSESSMENT
Diagnosing dementia in Down syndrome can be difficult due to factors including variability of baseline cognitive level, heterogeneous presentation and lack of robust diagnostic tools. Sheehan et al. [6] used clinical data from memory assessments of 85 people with Down syndrome, of whom 64 (73.5%) had an established diagnosis of dementia. Expert raters judged the cases as dementia or no dementia using their own clinical judgement and criteria from the International Classification of Disease (ICD) [7] and Diagnostic Statistical Manual of Mental Disorders-IV text revision (DSM-IV-TR) [8] . Clinicians' judgement was most accurate in identifying previously diagnosed cases (84.4%), compared with 70.3% with ICD-10 criteria and 56.3% with DSM-IV-TR criteria. Over time, the proportion of cases meeting international criteria increased. The DSM-IV has recently been replaced by the DSM-5, which introduced a new term for dementia (major neurocognitive disorder) as well as a new diagnostic category for mild neurocognitive disorder, which may help to make earlier diagnoses in Down syndrome, though the validity of this diagnosis in the context of intellectual disability needs to be established [9] .
Tsao et al. [10] used a cross-sectional study of 120 adults with Down syndrome without dementia aged 20-69 years to examine the 'normal' ageing process. They found age-related deterioration in both cognitive and social adaptation skills with interindividual variation, supporting the need for longitudinal assessment.
COMORBIDITIES
Comorbidities are common in Down syndrome, with well established links between Down syndrome and congenital heart disease, epilepsy, hypothyroidism, visual and hearing impairments and depression [5, 11] . The prevalence of most of these conditions does not change significantly in the presence of dementia [4 && ], requiring clinicians to remain observant for their emergence irrespective of cognitive decline.
Alexander et al. [5] found that incidence of epilepsy was elevated at all ages in Down syndrome, with a relative peak in adults 30 years and older (overall IRR 8.5; 7.3-9.8; P < 0.001 and for age 30 years and older IRR 15.2). Epilepsy was significantly more common in those with Down syndrome who already had a dementia diagnosis and occurred in more than 70% in a group with dementia [4 && ]. Epilepsy diagnosis was also a significant predictor of mortality (P ¼ 0.002), with those with an epilepsy diagnosis being 6.39 (2.02, 20.19) times more likely to die than those without.
Sobey et al. [12] used population-level data to examine incident cardiovascular events in 4081 people with Down syndrome versus 16 324 agematched controls. Haemorrhagic strokes were more common in people with Down syndrome than non-Down syndrome controls [risk ratio (RR) ¼ 3.31, 95% confidence interval (CI) 1.95, 5.60], as were ischaemic strokes (RR ¼ 3.76, 95% CI 2.39, 5.92). Increased risk for ischaemic (but not haemorrhagic) stroke was substantially attenuated on adjustment for cardiovascular risk factors. Haemorrhagic stroke is most likely to be due to cerebral amyloid angiopathy (CAA) that results from the deposition of amyloid-beta within the walls of
KEY POINTS
The overall risk for Alzheimer's disease in individuals with Down syndrome has been estimated to be more than 80% by age 65 years; the mean age at dementia diagnosis was 55.41 years.
PET imaging using amyloid-beta binding compounds has demonstrated significant amyloid binding in several brain regions in all individuals with Down syndrome by age 50 years.
Haemorrhagic strokes and epilepsy are both more common in individuals with Down syndrome and dementia than in controls, though intracerebral haemorrhage may be less common in Down syndrome than in those with duplication APP (the chromosome 21 gene implicated in Alzheimer's disease in Down syndrome) suggesting the presence of protective factors in Down syndrome.
Several new test batteries for more detailed phenotyping of cognitive abilities in Down syndrome have been described, though further validation may be required for use as outcome measures in clinical trials.
Several randomized treatment trials in Down syndrome populations have been published, showing some potential for EGCG to improve cognitive abilities before the onset of dementia in Down syndrome (though further trials are required), whereas vitamin E to reduce cognitive decline was found to be ineffective. cerebral blood vessels, which can eventually lead to intracerebral haemorrhage. Buss et al. [13] reviewed epidemiological and neuropathological studies comparing a rare form of familial Alzheimer's disease, caused by a duplication of the APP region on chromosome 21, with Down syndrome (three copies of chromosome 21). People with a familial duplication of APP appeared to have a higher frequency of intracerebral haemorrhage and possibly more extensive underlying vascular disorder. The authors concluded that trisomy 21 may provide partial protection against the prohaemorrhagic effects of APP duplication, and mechanisms related to amyloid-beta processing and clearance that may be responsible for differences in amyloid angiopathy require further examination. Down syndrome represents a unique opportunity to study the cerebrovascular features of ageing and Alzheimer's disease in the context of protection against atherosclerosis and lower blood pressure but with significant CAA [14] .
NEUROPSYCHOLOGY
Floor effects are a particular concern when requiring tools that are sufficiently sensitive for tracking decline. Several widely used tests have recently been shown to be unsuitable for those with more severe intellectual disability or dementia, highlighting the need to develop more sophisticated neuropsychological tools for this population. However, object memory, semantic verbal fluency, the cued recall task, Tower of London, the CANTAB paired associate learning and simple reaction time tasks and visuomotor precision tasks have been highlighted as suitable for discriminating between those with and without dementia and tracking dementia-related decline [15,16, [20] also appear to show deterioration from age 40 years onwards in dementia-free adults with Down syndrome [10] . A closer look at the cued recall task originally described by Hartle [21] found both free and total recall scores discriminate age and dementia status in those with Down syndrome [22] ; however, $35% of participants without dementia were excluded from the final sample for being unable to perform the task or cooperate, limiting the suitability of this test, particularly in those with lower functioning.
Validation of the NIH Toolbox (HealthMeasures, Evanston, Illinois, USA) Cognitive Battery for intellectual disability found that Flanker inhibition/ attention tasks, picture vocabulary, oral reading and picture sequence memory tasks were accessible to those with intellectual disability, whereas dimensional change card sort, pattern comparison and list sorting tasks showed large floor effects, limiting their suitability as trial outcome measures [23] . However, this study focused on a young sample (mean Down syndrome age ¼ 16 years), including individuals with Fragile X syndrome and idiopathic intellectual disability, thus the suitability of these tasks in older adults with Down syndrome remains unclear. The Rapid Assessment for Developmental Disabilities battery [24] and the NeuroTrax (Mindstreams, Newark, NJ, USA) Moderate to Severe Impairment Assessment Battery [25] have also been proposed as suitable tools for assessing cognitive function in those with Down syndrome, yet neither study reported full performance data.
A novel informant questionnaire addressing executive function, memory and language skills in Down syndrome was found to have high internal consistency, test-retest reliability and interrater reliability [26 & ]. This questionnaire could reliably discriminate between those with and without dementia, but showed no significant effects of age or sex, suggesting it could be useful for tracking cognitive decline, particularly where individuals are unable to engage with standard cognitive assessments.
DEMENTIA SYMPTOMS AND PRESYMPTOMATIC DECLINE IN DOWN SYNDROME
An ongoing debate is whether Alzheimer's disease presents differently in Down syndrome compared with older adults from the general population. Dick et al. [27] compared neuropsychological profiles of higher functioning Down syndrome individuals with dementia to individuals from the general population with advanced Alzheimer's disease, adjusting for sex and functional impairment. They found similarities, suggesting the underlying disorder in both cases may have comparable effects on cognitive profiles.
Previous studies suggested that behavioural and psychological symptoms and executive dysfunction may precede memory impairment in Down syndrome dementia [28, 29] . A recent cross-sectional study, however, suggested that immediate memory impairment is one of the earliest signs of dementia in people with Down syndrome [30] . Further longitudinal research is necessary to clarify the sequence of early changes in Down syndrome and their relationship to biomarkers such as neuroimaging.
It is important to remember that not all cases of cognitive decline in Down syndrome are the result of dementia. A rare phenomenon highlighted by recent research is that of childhood and adolescent 'regression' or 'disintegration ' 
NEUROIMAGING AND OTHER BIOMARKERS
Neuroimaging is a potential tool for monitoring biomarkers associated with progression from prodromal to symptomatic dementia in Down syndrome. Recent neuroimaging studies have used PET scans with amyloid-beta-binding compounds to characterize amyloid deposition and its association with dementia onset and symptoms. Sabbagh et al. [33 && ] used florbetapir PET imaging to assess mean standard uptake value ratios (SUVRs) as the primary outcome measure of fibrillar amyloid-beta burden in individuals with Down syndrome, Down syndrome with dementia and age-matched control participants without Down syndrome. Significant group differences in mean SUVRs were reported, with uptake higher in Down syndrome individuals compared with controls, and greater still in those with Down syndrome and dementia.
Jennings et al.
[34 && ] also used florbetapir PET imaging with individuals with Down syndrome, demonstrating that binding was strongly correlated with age, but not significantly associated with cognitive decline. Annus et al. [35 && ] used PET with Pittsburgh compound B (PiB; another amyloidbeta-binding compound) in adults with Down syndrome, finding PiB binding first in the striatum around age 40 years. By age 50 years, all had significant PiB binding in several brain regions. Age strongly predicted amyloid binding, and PiB binding was also significantly associated with diagnostic status and history of cognitive decline. Taken together, these studies suggest amyloid-imaging techniques could be used to stage individuals with Down syndrome in the presymptomatic period according to amyloid positive status on scans, and to characterize and monitor changes associated with the progression of Alzheimer's disease longitudinally.
Additional neuroimaging studies include the investigation of EEG biomarkers, with Salem et al. [36] reporting an association between cognitive decline and theta slowing. Proton magnetic resonance spectroscopy has also been used with the putative glial biomarker myoinositol, which highlighted the possible existence of an overall higher glial inflammatory component in Down syndrome individuals (independent of dementia status) compared with control participants [37] .
BIOMARKERS ASSOCIATED WITH COGNITIVE FUNCTIONING AND DECLINE IN DOWN SYNDROME
Plasma and CSF amyloid-beta levels are potential biomarkers for Alzheimer's disease. In individuals with Down syndrome, worse performance in a semantic verbal fluency task, poorer communication skills and a higher Dementia Questionnaire for Persons with Intellectual Disability score were recently found to be associated with higher plasma amyloidbeta42 concentrations [38] . Other Alzheimer's disease biomarkers, including those related to inflammation and oxidative stress, are also of interest. Individuals with Down syndrome may have a unique neuroinflammatory state even before the onset of dementia, with implications for therapeutic intervention [39] . Serum neutrophil gelatinaseassociated lipocalin levels, a newly identified neuroinflammatory constituent in Alzheimer's disease, were shown to be significantly increased in Down syndrome participants compared with those without Down syndrome, and positively associated with amyloid-beta42 in Down syndrome individuals with dementia and with amyloid-beta40 in Down syndrome individuals without dementia [40] . Declining plasma amyloid-beta42 and increasing pro-NGF (another inflammatory molecule) levels correlated with cognitive decline [41] , whereas urinary isoprostane 8,12-iso-iPF2alpha, a marker of oxidative stress, was associated with cognitive decline in a longitudinal study of Down syndrome [42] .
TREATMENT TRIALS
Existing treatments, particularly acetylcholine esterase inhibitors, may be beneficial in individuals with Down syndrome who have dementia, but conclusive evidence for efficacy is lacking [43] . Epigallocatechin-3-gallate (EGCG), a natural substance extracted from green tea, has been shown to inhibit DYRK1A (a kinase involved in Tau phosphorylation and implicated in Alzheimer's disease in Down syndrome, as the DYRK1A gene is situated on chromosome 21) [44] . De la Torre et al. [45 & ] subsequently conducted a phase-2 randomized placebo-controlled trial of EGCG in young adults with Down syndrome (n ¼ 84) in combination with cognitive training to improve cognitive functioning. After 12 months, those in the treatment arm had significantly higher scores in measures of visual recognition memory, inhibitory control and adaptive behaviour, though the improvements were modest and further trials are required to determine longer term safety and outcomes.
A randomized placebo-controlled trial of vitamin E to slow the progression of cognitive deterioration and dementia in individuals with Down syndrome was recently reported [46 && ]. Adults with Down syndrome older than 50 years (n ¼ 337) were randomly assigned to receive either 1000 IU of vitamin E orally twice daily or identical placebo for 3 years. There was no difference between drug and placebo on primary outcome (a brief praxis test), dementia rates or secondary outcomes, with a trend towards higher rates of adverse events in those treated with vitamin E.
Cooper et al. [15] reported a small randomized placebo-controlled feasibility trial (n ¼ 21) of simvastatin to prevent onset of dementia in older individuals with Down syndrome, using a memory for objects test as primary outcome. This test appeared to be sensitive to change, favouring the treatment, but the trial was too small to demonstrate benefit of the treatment.
CONCLUSION
Individuals with Down syndrome are a unique population for researching Alzheimer's disease and developing clinical trials of drugs for primary prevention (to avoid amyloid overproduction and deposition) and secondary prevention (to avoid onset of dementia after amyloid deposition), due to the relatively predictable onset of dementia in these adults. Such trials may benefit individuals with Down syndrome given their high dementia burden and may also serve as proof of concept for other forms of Alzheimer's disease, yet improvements in outcome measures and trial design are required [47] . Although recent research has improved our understanding of dementia in Down syndrome, further work is necessary to understand the progression of disorder and its relationship with the development of symptoms during the presymptomatic period of Alzheimer's disease in Down syndrome. Prospective longitudinal studies offer great promise for our future understanding of Alzheimer's disease in Down syndrome [18, 48] .
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